FDAsafety guidance72% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (immunology) as Kite Pharma.
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Neurology · Autoimmune Diseases
- Sub-indication
- Immunology
Related signal: KITE-363 Phase 1 Study Initiated for Autoimmune Neurologic Diseases